Sera Prognostics (SERA) & Its Peers Critical Comparison

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 public companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare Sera Prognostics to related companies based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and price targets for Sera Prognostics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	0	1	4	0	2.80
Sera Prognostics Competitors	353	1096	1762	47	2.46

Sera Prognostics currently has a consensus price target of $18.50, indicating a potential upside of 1,150.00%. As a group, “Medical laboratories” companies have a potential upside of 105.01%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than its rivals.

Valuation & Earnings

This table compares Sera Prognostics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sera Prognostics	$80,000.00	-$35.01 million	-0.34
Sera Prognostics Competitors	$1.09 billion	$56.91 million	8.01

Sera Prognostics’ rivals have higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

63.2% of Sera Prognostics shares are owned by institutional investors. Comparatively, 61.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 20.1% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Sera Prognostics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-38,185.05%	-58.37%	-30.80%
Sera Prognostics Competitors	-1,687.27%	-37.96%	-17.61%

Summary

Sera Prognostics rivals beat Sera Prognostics on 8 of the 12 factors compared.

Sera Prognostics Company Profile (Get Rating)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.